Biocartis Group N.V. | Ownership
Companies that own Biocartis Group N.V.
CAPFI DELEN Asset Management SA
3,191,254
6.22%
357,319
0.19%
06/30/2018
Sycomore Asset Management SA
2,708,420
5.28%
407,294
1.2%
12/31/2017
OppenheimerFunds, Inc.
2,600,000
5.07%
2,600,000
0.02%
12/06/2017
KBC Asset Management NV
923,256
1.8%
333,487
0.07%
02/28/2018
Degroof Petercam Asset Management SA
446,077
0.87%
13,063
0.04%
12/31/2017
BNP Paribas Asset Management Belgium SA
335,347
0.65%
0
0.04%
07/31/2018
Tocqueville Finance SA
306,126
0.6%
0
0.26%
07/31/2018
BLI - Banque de Luxembourg Investments SA
214,600
0.42%
0
0.04%
07/31/2018
Candriam Belgium SA
206,502
0.4%
1,650
0.01%
07/31/2018
Aviva Investors France SA
200,000
0.39%
25,000
0.05%
08/31/2018
| Address |
Generaal de Wittelaan 11 B3
Mechelen VL 2800
Belgium
|
|
Employees
|
- |
| Website |
http://www.biocartis.com |
| Updated |
07/08/2019 |
| Biocartis Group NV is a commercial stage molecular diagnostics company, which engaegs in the provision of diagnostic solutions. It operates through MDx Idylla™ platform, an automated sample-to-result, real-time polymerase chain reaction system that offers molecular information from virtually any biological sample. The company was founded by Renaud Philippe, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium. |
